TP53 and breast carcinoma: p53 currently features as one of five antibodies in the Mammostrat (Clarient, Inc., Aliso Viejo, CA, USA) IHC test shown to be of predictive value in ER+, tamoxifen-treated early breast cancer (Ring et al, 2006; Bartlett et al, 2010).